Sorin Group perfusion system – Heater Cooler 3T devices 의 리콜

Department of Health, Therapeutic Goods Administration에 따르면, 해당 리콜 는 Australia 에서 LivaNova Australia Pty Ltd 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

의료기기에 문제가 생겼을 경우 제조사가 이를 바로잡거나 시장에서 회수하는 조치를 말한다. 회수(Recall)는 의료기기에 결함이 있거나, 건강에 위협이 되거나, 또는 결함도 있고 건강에도 위협이 될 경우에 발생한다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Recall
  • 사례 ID
    RC-2017-RN-01368-1
  • 사례 위험등급
    Class I
  • 사례 시작날짜
    2017-10-27
  • 사례 국가
  • 사례 출처
    DHTGA
  • 사례 출처 URL
  • 비고 / 경고
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • 데이터 추가 비고
  • 원인
    Livanova is issuing a recall for product correction to inform users about the retrofit of their heater cooler 3t devices to implement a vacuum and sealing upgrade. this modification to the internal design of the 3t heater-cooler device will collect any aerosols that are potentially contaminated with nontuberculous mycobacterium (ntm), preventing those aerosols from entering into the sterile operating field.Livanova is also notifying that the 3t device will be suspended from the australian register of therapeutic goods (artg) beginning 8 november 2017 for a period of up to 6 months. the reason for this suspension is that the minncare disinfectant is not listed on the artg with the same classification as the 3t device. however, during this period, livanova will be able to supply loan units on an as-needed, no-charge basis to ensure continuity of clinical practice.
  • 조치
    LivaNova has completed the development of a TGA approved correction that mitigates against this potential contamination by preventing dispersion of aerosols produced by the heater-cooler in the operating room. This correction will be implemented by an onsite enhancement of units currently in use by LivaNova service personnel or a local agent. Although this issue is less likely when the 3T device’s water system is maintained according to the current IFU, this product correction will mitigate against the reasonably foreseeable hazard of patient infection which may be potentiated by poor maintenance practices.

Device

Manufacturer